Back to Search
Start Over
Adult Xp11.2 translocation renal cell carcinoma managed effectively with pazopanib
- Source :
- BMJ Case Rep
- Publication Year :
- 2021
- Publisher :
- BMJ, 2021.
-
Abstract
- Xp11.2 translocation renal cell carcinoma (TRCC) is a rare and aggressive variant of renal cell carcinoma (RCC) when presenting in adults. We report a case of a man in his early 40s who was diagnosed with stage III Xp11.2 TRCC and underwent radical nephrectomy. Seven months following the surgery, an adrenal nodule and bilateral pulmonary nodules were discovered. He underwent cryoablation of the adrenal nodule and systemic treatment with daily pazopanib. He displayed stable disease for approximately 6 years. Following this period, multiple hospitalisations interrupted daily pazopanib therapy resulting in progression of disease. His regimen was then changed to ipilimumab and nivolumab, followed by current daily therapy with axitinib. The patient now shows stable disease in his 10th year after diagnosis. This case study demonstrates the efficacy of pazopanib for metastatic Xp11.2 TRCC and warrants further investigation to supplement the guidelines regarding the use of targeted therapy for TRCC.
- Subjects :
- Adult
Male
0301 basic medicine
medicine.medical_specialty
Indazoles
medicine.medical_treatment
Urology
Case Report
Ipilimumab
Translocation, Genetic
Targeted therapy
Pazopanib
03 medical and health sciences
0302 clinical medicine
Renal cell carcinoma
Humans
Medicine
Carcinoma, Renal Cell
Chromosomes, Human, X
Sulfonamides
business.industry
Cryoablation
General Medicine
medicine.disease
Kidney Neoplasms
Nephrectomy
Axitinib
Pyrimidines
030104 developmental biology
030220 oncology & carcinogenesis
Nivolumab
business
medicine.drug
Subjects
Details
- ISSN :
- 1757790X
- Volume :
- 14
- Database :
- OpenAIRE
- Journal :
- BMJ Case Reports
- Accession number :
- edsair.doi.dedup.....5c8b847bb4fc733aa2317365c7ebf22e
- Full Text :
- https://doi.org/10.1136/bcr-2021-243058